Genetic basis for prediction of non-responders to dietary plant sterol intervention (GenePredict-PS): a study protocol for a double-blind, placebo-controlled, randomized two-period crossover study

Maryam Shamloo, Matthew J Granger, Elke A Trautwein, James D House, Dylan MacKay, Maryam Shamloo, Matthew J Granger, Elke A Trautwein, James D House, Dylan MacKay

Abstract

Background: Functional food ingredients and natural health products have been demonstrated to reduce disease risk and thereby help to lower health care costs across populations at risk for chronic or degenerative diseases. However, typically a wide range of interindividual variability exists in response across individuals to nutritional and natural health product bioactives, such as plant sterols (PS). This study aims to determine and utilize information on the associations between genosets and the degree of responsiveness to dietary PS intervention, with a long-term objective of developing genetic tests to predict responses to PS.

Methods: This clinical trial is designed as a double-blind, placebo controlled, randomized two-period crossover study. Sixty-four eligible participants with the specific a priori-determined single nucleotide polymorphisms (SNPs) associated with a responsiveness to PS will consume PS or a placebo treatment for two 4-week periods. The PS treatment consists of two daily single portions of margarine, each providing 1 g PS during the PS period (2.0 g/day of PS in total). The placebo will be an identical margarine containing no added PS. Low-density lipoprotein cholesterol (LDL-C) responsiveness to the controlled administration of PS will be investigated as the primary outcome, and the associations between interindividual genoset variabilities and response to PS consumption will be determined.

Discussion: This research will provide further insight into whether the associations between previously identified SNPs and the response of LDL-C to PS consumption can be used in a predictive manner. It will also provide insight into the complexities of undertaking a nutrigenetic trial with prospective recruitment based on genotype.

Trial registration: ClinicalTrials.gov: Identifier: NCT02765516. Registered on 6 May 2016.

Keywords: Cholesterol; Genetic; Plant sterols; Prediction; SNPs.

Conflict of interest statement

ET is employed by Upfield™ marketed food products with added plant sterols. All other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schematic flow diagram of the trial protocol

References

    1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi: 10.1093/eurheartj/ehx144.
    1. Storey BC, Staplin N, Haynes R, Reith C, Emberson J, Herrington WG, et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney Int. 2018;93(4):1000–1007. doi: 10.1016/j.kint.2017.09.011.
    1. Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016;10(3):472–489. doi: 10.1016/j.jacl.2015.11.010.
    1. Shrestha S, Volek JS, Udani J, Wood RJ, Greene CM, Aggarwal D, et al. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr. 2006;136(10):2492–2497. doi: 10.1093/jn/136.10.2492.
    1. Rosenthal RL. Effectiveness of altering serum cholesterol levels without drugs. Baylor Univ Med Cent Proc. 2000;13(4):351–355. doi: 10.1080/08998280.2000.11927704.
    1. Rideout TC. Getting personal: considering variable interindividual responsiveness to dietary lipid-lowering therapies. Curr Opin Lipidol. 2011;22(1):37–42. doi: 10.1097/MOL.0b013e3283414e71.
    1. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. Mayo Clin Proc. 2003;78(8):965–78.
    1. Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr. 2009;139(2):271–84.
    1. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214–19.
    1. Rideout TC, Harding SV, Mackay D, Abumweis SS, Jones PJ. High basal fractional cholesterol synthesis is associated with nonresponse of plasma LDL cholesterol to plant sterol therapy. Am J Clin Nutr. 2010;92(1):41–46. doi: 10.3945/ajcn.2009.29073.
    1. Mackay DS, Gebauer SK, Eck PK, Baer DJ, Jones PJ. Lathosterol-to-cholesterol ratio in serum predicts cholesterol-lowering response to plant sterol consumption in a dual-center, randomized, single-blind placebo-controlled trial. Am J Clin Nutr. 2015;101(3):432–439. doi: 10.3945/ajcn.114.095356.
    1. Mackay DS, Eck PK, Rideout TC, Baer DJ, Jones PJ. Cholesterol ester transfer protein polymorphism rs5882 is associated with triglyceride-lowering in response to plant sterol consumption. Appl Physiol Nutr Metab. 2015;40(8):846–849. doi: 10.1139/apnm-2015-0039.
    1. MacKay DS, Eck PK, Gebauer SK, Baer DJ, Jones PJ. CYP7A1-rs3808607 and APOE isoform associate with LDL cholesterol lowering after plant sterol consumption in a randomized clinical trial. Am J Clin Nutr. 2015;102(4):951–957. doi: 10.3945/ajcn.115.109231.
    1. Varady KA, Houweling AH, Jones PJ. Effect of plant sterols and exercise training on cholesterol absorption and synthesis in previously sedentary hypercholesterolemic subjects. Transl Res. 2007;149(1):22–30. doi: 10.1016/j.trsl.2006.06.002.
    1. Rudkowska I, AbuMweis SS, Nicolle C, Jones PJ. Association between non-responsiveness to plant sterol intervention and polymorphisms in cholesterol metabolism genes: a case-control study. Appl Physiol Nutr Metab. 2008;33(4):728–734. doi: 10.1139/H08-041.
    1. Wilson CP, McNulty H, Ward M, Strain JJ, Trouton TG, Hoeft BA, et al. Blood pressure in treated hypertensive individuals with the <i>MTHFR</i> 677TT genotype is responsive to intervention with riboflavin. Hypertension. 2013;61(6):1302–1308. doi: 10.1161/HYPERTENSIONAHA.111.01047.
    1. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224. doi: 10.1038/s41588-018-0183-z.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj